Development of HEK293T-produced recombinant receptor-Fc proteins as potential candidates against canine distemper virus.

Lingling Song, Hu Shan, Juan Huang
Author Information
  1. Lingling Song: College of Veterinary Medicine, Qingdao Agricultural University, Qingdao, China.
  2. Hu Shan: College of Veterinary Medicine, Qingdao Agricultural University, Qingdao, China.
  3. Juan Huang: College of Veterinary Medicine, Qingdao Agricultural University, Qingdao, China.

Abstract

Canine distemper (CD) is a highly contagious viral disease worldwide. Although live attenuated vaccine is available as a preventive measure against the disease, cases of vaccination failure highlight the importance of potential alternative agent against canine distemper virus (CDV). CDV infects cells mainly by binding signaling lymphocyte activation molecule (SLAM) and Nectin-4 receptor. Here, to develop a new and safe antiviral biological agent for CD, we constructed and expressed CDV receptor proteins fused with Fc region of canine IgG-B, namely, SLAM-Fc, Nectin-Fc and SLAM-Nectin-Fc in HEK293T cells, and antiviral activity of these receptor-Fc proteins was subsequently evaluated. The results showed that the receptor-Fc proteins efficiently bound to receptor binding domain (RBD) of CDV-H, meanwhile, these receptor-Fc proteins competitively inhibited the binding of His-tagged receptor proteins (SLAM-His or Nectin-His) to CDV-H-RBD-Flag protein. Importantly, receptor-Fc proteins exhibited potent anti-CDV activity . Treatment with receptor-Fc proteins at the pre-entry stage dramatically suppressed CDV infectivity in Vero cells stably expressing canine SLAM. The minimum effective concentration (MEC) of SLAM-Fc, Nectin-Fc and SLAM-Nectin-Fc was 0.2 μg/mL, 0.2 μg/mL, 0.02 μg/mL. The 50% inhibition concentration (IC) of three proteins was 0.58 μg/mL, 0.32 μg/mL and 0.18 μg/mL, respectively. Moreover, treatment with receptor-Fc proteins post viral infection can also inhibit CDV reproduction, the MEC of SLAM-Fc, Nectin-Fc and SLAM-Nectin-Fc was same as pre-treatment, and the IC of receptor-Fc proteins was 1.10 μg/mL, 0.99 μg/mL and 0.32 μg/mL, respectively. The results suggested that the receptor-Fc proteins were more effective for pre-entry treatment than post-infection treatment, furthermore, SLAM-Nectin-Fc was more effective than SLAM-Fc and Nectin-Fc. These findings revealed the receptor-Fc proteins were promising candidates as inhibitor against CDV.

Keywords

References

  1. Int J Cardiol. 2020 Feb 1;300:217-218 [PMID: 31399296]
  2. Proc Natl Acad Sci U S A. 2023 Feb 7;120(6):e2208866120 [PMID: 36716368]
  3. Virus Res. 2022 Sep;318:198841 [PMID: 35649483]
  4. Res Vet Sci. 2013 Oct;95(2):717-24 [PMID: 23664014]
  5. Vaccine. 2020 Jul 31;38(35):5653-5658 [PMID: 32651113]
  6. Virology. 2014 Apr;454-455:109-17 [PMID: 24725937]
  7. Front Plant Sci. 2021 Jan 07;11:604663 [PMID: 33584747]
  8. Biotechnol J. 2021 Jun;16(6):e2000566 [PMID: 33481336]
  9. Kidney Int. 2018 Jul;94(1):114-125 [PMID: 29691064]
  10. Virus Genes. 2021 Jun;57(3):266-275 [PMID: 33950332]
  11. Animals (Basel). 2022 Oct 20;12(20): [PMID: 36290237]
  12. Biotechnol Rep (Amst). 2019 Feb 08;21:e00312 [PMID: 30847284]
  13. Viruses. 2022 Jul 12;14(7): [PMID: 35891500]
  14. Int Immunopharmacol. 2022 Aug;109:108783 [PMID: 35561479]
  15. PLoS Pathog. 2021 Apr 9;17(4):e1009501 [PMID: 33836016]
  16. Curr Opin Virol. 2020 Apr;41:38-45 [PMID: 32344228]
  17. Pathogens. 2021 Apr 30;10(5): [PMID: 33946447]
  18. Pathogens. 2022 Dec 29;12(1): [PMID: 36678405]
  19. Brain Behav. 2021 Jan;11(1):e01920 [PMID: 33300690]
  20. J Vet Diagn Invest. 2021 Jul;33(4):640-647 [PMID: 33870768]
  21. Life (Basel). 2022 Feb 15;12(2): [PMID: 35207575]
  22. Microbiol Immunol. 2022 Dec;66(12):552-563 [PMID: 36151905]
  23. BMC Vet Res. 2021 Aug 6;17(1):266 [PMID: 34362358]
  24. J Virol. 2018 Aug 29;92(18): [PMID: 29997204]
  25. Comput Math Methods Med. 2022 Feb 17;2022:6244175 [PMID: 35222687]
  26. Viruses. 2019 Aug 19;11(8): [PMID: 31430904]
  27. Transbound Emerg Dis. 2022 Jul;69(4):e944-e952 [PMID: 34724331]
  28. J Virol Methods. 2017 Oct;248:207-211 [PMID: 28760649]
  29. J Virol. 2018 Jul 17;92(15): [PMID: 29793948]
  30. mSphere. 2021 Apr 14;6(2): [PMID: 33853875]
  31. BMC Vet Res. 2019 Sep 2;15(1):316 [PMID: 31477101]
  32. Vaccine. 2021 Oct 29;39(45):6601-6613 [PMID: 34642088]
  33. Curr Pharm Biotechnol. 2010 Apr;11(3):241-5 [PMID: 20210749]
  34. J Gen Virol. 2021 Mar;102(3): [PMID: 33416466]
  35. Mol Ther Oncolytics. 2019 Dec 14;16:20-29 [PMID: 31909182]
  36. BMC Vet Res. 2020 Nov 19;16(1):448 [PMID: 33213424]
  37. J Virol. 2012 Sep;86(18):10207-10 [PMID: 22761370]
  38. Viruses. 2019 Oct 14;11(10): [PMID: 31615092]
  39. Brain Nerve. 2019 May;71(5):525-530 [PMID: 31089000]
  40. Front Vet Sci. 2021 Jan 21;7:570283 [PMID: 33585591]
  41. Vet Microbiol. 2012 Mar 23;155(2-4):198-206 [PMID: 21982126]
  42. J Vet Diagn Invest. 2020 Jul;32(4):598-603 [PMID: 32560597]

Word Cloud

Created with Highcharts 10.0.0proteinsreceptor-Fcμg/mL0CDVcaninedistemperreceptorSLAM-FcNectin-FcSLAM-Nectin-FcagentviruscellsbindingSLAMantiviraleffectivetreatmentCDviraldiseasepotentialNectin-4biologicalactivityresultsproteinpre-entryconcentrationMEC2IC32respectivelycandidatesCaninehighlycontagiousworldwideAlthoughliveattenuatedvaccineavailablepreventivemeasurecasesvaccinationfailurehighlightimportancealternativeinfectsmainlysignalinglymphocyteactivationmoleculedevelopnewsafeconstructedexpressedfusedFcregionIgG-BnamelyHEK293TsubsequentlyevaluatedshowedefficientlybounddomainRBDCDV-HmeanwhilecompetitivelyinhibitedHis-taggedSLAM-HisNectin-HisCDV-H-RBD-FlagImportantlyexhibitedpotentanti-CDVTreatmentstagedramaticallysuppressedinfectivityVerostablyexpressingminimum0250%inhibitionthree5818Moreoverpostinfectioncanalsoinhibitreproductionpre-treatment11099suggestedpost-infectionfurthermorefindingsrevealedpromisinginhibitorDevelopmentHEK293T-producedrecombinantFc-fusion

Similar Articles

Cited By